Bruntwood SciTech has completed a £60m laboratory and office building at Manchester Science Park, marking one of the most significant life sciences property investments outside the so-called 'golden triangle' of Oxford, Cambridge and London this year. The building, designed to provide grade-A wet lab and office accommodation, is aimed squarely at the growing cluster of biotech, medtech and diagnostics companies that have been expanding across the North West, and it arrives at a moment when demand for specialist science and innovation space is comfortably outstripping supply in most UK regional cities.
For property investors, this development matters far beyond its immediate footprint. The UK life sciences real estate sector has become one of the few genuine growth stories in commercial property over the past three years, with vacancy rates for grade-A lab space in city-centre locations often below 5%, compared with double-digit vacancy in some traditional office markets. Manchester, alongside Birmingham and Leeds, has positioned itself as a credible alternative to the saturated and prohibitively expensive Cambridge cluster, where rents for lab space can exceed £55 per square foot. Bruntwood SciTech — the joint venture between Bruntwood and Legal & General, backed also by Greater Manchester Pension Fund — has effectively built a strategy around this arbitrage, and this £60m scheme is the latest instalment in a pipeline that now runs into the hundreds of millions across Manchester, Alderley Park, Liverpool and Birmingham.
The economics here are instructive. Life sciences and innovation space typically commands rental premiums of 20–40% over conventional office stock, reflecting the specialist fit-out costs — ventilation, power loading, vibration control — that make these buildings expensive to construct but difficult for occupiers to replicate elsewhere. That premium, combined with long lease terms often running to 10–15 years with institutional-grade covenants from university spinouts, NHS-linked ventures and pharmaceutical tenants, makes the asset class highly attractive to pension funds and insurers seeking inflation-linked income streams. It is precisely this profile that has drawn Legal & General so heavily into the Bruntwood SciTech partnership, and why other institutional capital — including from the US and Gulf sovereign wealth funds — has been circling similar developments in Leeds and Newcastle.
Regionally, the implications diverge. Manchester's science and innovation district, anchored by the university, Alderley Park and now this new building, is rapidly becoming a genuine cluster rather than a scattering of individual assets — the kind of agglomeration effect that drives sustained rental growth rather than one-off yield compression. Birmingham, by contrast, is still building critical mass around its Life Sciences Park at Birmingham Health Innovation Campus, while Leeds is leaning on its strength in medtech and health data. London remains the deepest market by capital value, but with prime lab rents pushing towards £70 per square foot in areas like King's Cross, cost-conscious occupiers — particularly early-stage biotechs reliant on grant funding rather than venture capital — are increasingly looking north. Surrey's cluster around Guildford and the M3 corridor continues to serve pharmaceutical incumbents, but lacks the scale expansion currently underway in the major northern cities.
Looking ahead 6–12 months, expect further announcements of speculative lab and innovation-space development in secondary UK cities, underwritten by institutional joint ventures rather than pure developer risk. Interest rate stabilisation, with the Bank of England base rate now easing from its 2023 peak, is improving development viability for these higher-capex schemes, and several other regional science parks — including at Newcastle Helix and Liverpool's Knowledge Quarter — are likely to see comparable capital commitments. For buy-to-let landlords and residential investors, the read-across is indirect but real: successful science parks generate high-value employment clusters that support premium rental demand in surrounding neighbourhoods, a dynamic already visible in areas adjacent to Alderley Park and around Manchester's Oxford Road corridor. First-time buyers in these micro-markets should expect continued upward pressure on both sale prices and rents as employment growth outpaces housing delivery.
For commercial investors and developers, the message is unambiguous: UK life sciences property has moved from a niche institutional play to a core allocation strategy, and the regional cities capable of demonstrating genuine cluster depth — anchor universities, teaching hospitals, existing lab stock and patient long-term capital — will command the premium. Manchester, through Bruntwood SciTech's sustained investment, has arguably done more than any city outside London to prove that model works at scale. Developers without a credible life sciences occupier pipeline should be cautious about entering the sector opportunistically; the capital intensity of these buildings punishes speculative timing far more severely than conventional office or industrial development.
